Preclinical Characterization of GLS-010 (Zimberelimab), a Novel Fully Human Anti-PD-1 Therapeutic Monoclonal Antibody for Cancer

BACKGROUND: Zimberelimab (GLS-010) is a novel fully human monoclonal immunoglobulin G4 (IgG4) against the programmed cell death-1 (PD-1) receptor. AIM: To evaluate the affinity, competitive blocking capability, T cell activation effect, cytotoxic effector functions by Fc, preliminary anti-tumor acti...

Descripción completa

Detalles Bibliográficos
Autores principales: Lou, Beilei, Wei, Hua, Yang, Fang, Wang, Shicong, Yang, Baotian, Zheng, Yong, Zhu, Jiman, Yan, Shaoyu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8479189/
https://www.ncbi.nlm.nih.gov/pubmed/34604074
http://dx.doi.org/10.3389/fonc.2021.736955

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8479189/
https://www.ncbi.nlm.nih.gov/pubmed/34604074
http://dx.doi.org/10.3389/fonc.2021.736955

Ejemplares similares